ALTME.PA Stock - TME Pharma N.V.
Unlock GoAI Insights for ALTME.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $19,000 | $17,000 | N/A | $33,000 | $35 |
| Gross Profit | $-78,000 | $-127,000 | $-92,000 | $-65,967 | $-62,965 |
| Gross Margin | -410.5% | -747.1% | N/A | -199.9% | -179900.0% |
| Operating Income | $-5,277,000 | $-5,624,000 | $-12,029,000 | $-13,267,000 | $-5,769,000 |
| Net Income | $-5,722,000 | $-6,736,000 | $-15,132,000 | $-14,452,000 | $-10,405,000 |
| Net Margin | -30115.8% | -39623.5% | N/A | -43793.9% | -29728571.4% |
| EPS | $-0.21 | $-1.34 | $-12.86 | $-21.90 | $-32.16 |
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
Visit WebsiteEarnings History & Surprises
ALTME.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Apr 25, 2025 | — | $-0.09 | — | — |
Q3 2024 | Jul 31, 2024 | — | $-0.12 | — | — |
Q2 2024 | Apr 25, 2024 | — | $-0.46 | — | — |
Q4 2023 | Oct 27, 2023 | — | $-1.09 | — | — |
Q2 2023 | Apr 24, 2023 | — | $-3.31 | — | — |
Q4 2022 | Oct 26, 2022 | — | $-11.47 | — | — |
Q2 2022 | Apr 22, 2022 | — | $-10.85 | — | — |
Q4 2021 | Oct 26, 2021 | — | $-11.07 | — | — |
Q2 2021 | Apr 29, 2021 | — | $-10.72 | — | — |
Q3 2020 | Jul 13, 2020 | — | $-25.84 | — | — |
Q2 2020 | Apr 22, 2020 | — | $6.41 | — | — |
Q4 2019 | Oct 24, 2019 | — | $-25.82 | — | — |
Q2 2019 | Apr 12, 2019 | — | $-119.97 | — | — |
Q4 2018 | Oct 11, 2018 | — | $-169.69 | — | — |
Q2 2018 | May 1, 2018 | — | $-141.62 | — | — |
Q4 2017 | Oct 30, 2017 | — | $-110.36 | — | — |
Q2 2017 | May 1, 2017 | — | $-156.47 | — | — |
Q4 2016 | Oct 26, 2016 | — | $-550.36 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-641.89 | — | — |
Q2 2015 | Jun 30, 2015 | — | $-512.50 | — | — |
Latest News
Frequently Asked Questions about ALTME.PA
What is ALTME.PA's current stock price?
What is the analyst price target for ALTME.PA?
What sector is TME Pharma N.V. in?
What is ALTME.PA's market cap?
Does ALTME.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ALTME.PA for comparison